Who Owns Hikma Company?

Hikma Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Hikma Pharmaceuticals today?

Hikma Pharmaceuticals began in Amman in 1978 and went public on the London Stock Exchange in 2005, shifting from a family firm to a global pharma listed company. The IPO funded rapid expansion, stronger governance, and institutional investor presence.

Ownership now blends the founding Darwazah family's significant stake with substantial global institutional investors, shaping strategy and capital allocation while balancing long-term growth and market accountability. See Hikma Porter's Five Forces Analysis.

Samih Darwazah founded Hikma Pharmaceuticals in 1978, initially funding and controlling the business through the Darwazah family; early ownership was fully private and concentrated within Samih and his sons, Said and Mazen.

Founding vision

Samih Darwazah brought Eli Lilly experience to Jordan to raise regional manufacturing standards.

Family control

Ownership was concentrated within the Darwazah family; equity remained private through the 1980s.

Funding approach

Early growth relied on internal cash flows and local bank credit facilities rather than public equity.

Geographic focus

Initial manufacturing base was established in Jordan, with subsequent expansion to Portugal.

IFC participation

The International Finance Corporation took a minority stake in the 1980s–1990s to support regulated-market expansion.

Governance impact

IFC investment professionalized reporting and operations while buy-sell clauses preserved family control.

Early ownership arrangements prioritized family voting control; IFC’s minority stake provided liquidity and an exit path without diluting strategic direction.

Key facts on founders and early ownership

Core facts about Hikma’s founding ownership and early institutional backing.

• Founded in 1978 by Samih Darwazah; initial equity wholly family-owned.
• Primary funding sources: internal cash flow and local credit; no early public equity.
• IFC minority investment occurred in the 1980s–1990s, aiding entry to regulated markets.
• Early shareholder agreements included buy-sell clauses to retain family control while allowing IFC exit.

For broader context on Hikma’s strategic growth and later ownership evolution, see Growth Strategy of Hikma.

Hikma SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership of Hikma shifted from a family-controlled private group to a predominantly institutional base after the November 2005 IPO (valuing the company at ~£450 million), with key inflections including the 2016 Roxane acquisition and Boehringer Ingelheim’s subsequent entry and 2020 exit; as of Q3 2025 the Darwazah family via Darhold Limited remains the cornerstone holder.

As of Q3 2025 Darhold Limited (Darwazah family vehicle) holds approximately 24.8%, while major institutional investors—BlackRock (~6.2%), The Vanguard Group (~3.5%), Norges Bank and Schroders—collectively shape governance, ESG engagement and capital return policies.

Ownership Snapshot and Governance Role

Major shareholders determine strategic direction through board influence and active stewardship, balancing family continuity with institutional accountability.

• Darhold Limited: cornerstone ~24.8%
• BlackRock Inc.: ~6.2%
• The Vanguard Group: ~3.5%
• Other institutions: Norges Bank, Schroders and global asset managers

For context on Hikma’s wider strategic positioning and shareholder implications see Marketing Strategy of Hikma

Hikma PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors of Hikma is chaired by Executive Chairman Said Darwazah, with Riad Mishlawi serving as CEO since 2023; the board is majority independent non-executive directors in line with the London Stock Exchange listing requirements and oversight of the company’s strategic direction.

Hikma’s governance follows a one-share-one-vote model, aligning voting power with economic interest while the Darwazah family, via Darhold Limited, holds near 25% and can block 75% supermajority resolutions; the board has increased transparency on R&D, US Generics and biosimilars amid occasional activist scrutiny.

Board composition and voting power

Major governance features and shareholder dynamics affecting strategic decisions.

• One-share-one-vote ensures proportional voting tied to economic stake
• Darhold Limited holds near 25%, enabling de facto veto on 75% matters
• Majority independent non-executive directors required by LSE listing
• Board response: improved reporting on US Generics turnaround and biosimilars expansion

For context on Hikma’s mission and values that inform governance, see Mission, Vision & Core Values of Hikma

Hikma Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

From 2023 to 2025 Hikma ownership trends shifted toward consolidation via aggressive share buybacks and rising institutional interest, particularly from ESG-focused funds, while the Darwazah family remains a cornerstone shareholder ensuring leadership continuity.

Share repurchases reflect a sector-wide preference for returning capital rather than pursuing dilutive acquisitions, while potential equity-based deals to enter high-margin specialty markets could modestly dilute the Darwazah family stake over time; no privatization or US secondary listing confirmed as of early 2026.

Buyback and EPS impact

The 2024 150 million USD buyback raised EPS and strengthened per-share metrics used by institutional investors and analysts.

Injectables growth outlook

Management forecasted 5–7% revenue growth for Injectables in 2025, drawing interest from growth-oriented funds.

ESG ownership trend

By 2025 more than 15% of institutional holders had ESG mandates, reflecting Hikma's role in affordable medicines and carbon-neutral manufacturing commitments.

Darwazah family position

Analysts expect the Darwazah family to retain a cornerstone stake for leadership continuity, though future equity transactions for expansion could alter percentage holdings.

For related detail on revenue mix and strategic drivers that influence Hikma corporate ownership and investor appetite see Revenue Streams & Business Model of Hikma

Hikma Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔